Journal Article

Chemotherapy-Related Amenorrhea and Menopause in Young Chinese Breast Cancer Patients: Analysis on Incidence, Risk Factors and Serum Hormone Profiles

Suen, Joyce J. S., Tang, Nelson L. S., Lee, Kun M., Ng, Rita, Yip, Claudia H. W., Tam, Wing H., Pang, Elizabeth, Koh, Jane, Mo, Frankie K. F., Yeo, Winnie, Liem, Giok S., Yip, Christopher C. H., Kong, Grace W. S.

2015

Overview

In this prospective cross-sectional study on young premenopausal breast cancer patients, the objectives were to: determine the incidences of chemotherapy-related amenorrhea (CRA) and menopause (CRM); identify associated factors; and assess plasma levels of estradiol (E2) and follicular stimulating hormone (FSH) among patients who developed menopause. Eligibility criteria include Chinese stage I-III breast cancer patients, premenopausal, age ≤45 at breast cancer diagnosis, having received adjuvant chemotherapy, within 3-10 years after breast cancer diagnosis. Detailed menstrual history prior to and after adjuvant treatment was taken at study entry. Patients' background demographics, tumor characteristics and anti-cancer treatments were collected. The rates of CRA and CRM were determined. Analysis was conducted to identify factors associated with CRM. For postmenopausal patients, levels of E2 and FSH were analyzed. 286 patients were recruited; the median time from breast cancer diagnosis to study entry was 5.0 years. 255 patients (91.1%) developed CRA. Of these, 66.7% regained menstruation. At the time of study entry, 137 (48.9%) had developed CRM, amongst whom 84 were age ≤45. On multivariate analysis, age was the only associated factor. Among patients with CRM, the median FSH was 41.0 IU/L; this was significantly lower in those who were taking tamoxifen compared to those who were not (20.1 vs. 59.7 IU/L, p<0.0001). The E2 level was <40 pmol/L; there was no difference between those who were still on tamoxifen or not. After adjuvant chemotherapy, the majority of young Chinese breast cancer patients developed CRA; ~50% developed CRM, with 61% at age ≤45. Age at diagnosis is the only factor associated with CRM. FSH level may be affected by tamoxifen intake.

• Publisher: Public Library of Science,Public Library of Science (PLoS)
• Subject: 17β-Estradiol / Adult / Age / Amenorrhea / Amenorrhea - blood / Amenorrhea - chemically induced / Amenorrhea - epidemiology / Antineoplastic Agents - adverse effects / Antineoplastic Agents - therapeutic use / Breast cancer / Breast Neoplasms - blood / Breast Neoplasms - drug therapy / Cancer / Cancer therapies / Care and treatment / Chemotherapy / Chemotherapy, Adjuvant - adverse effects / China / Cross-Sectional Studies / Cytotoxicity / Demographics / Demography / Diagnosis / Estradiol - blood / Female / Follicle Stimulating Hormone - blood / Follicle-stimulating hormone / Gynecology / Health aspects / Health risks / Hormone replacement therapy / Humans / Incidence / Medical diagnosis / Menopause / Menopause, Premature - blood / Menstruation / Middle Aged / Multivariate analysis / Obstetrics / Oncology / Patients / Plasma levels / Post-menopause / Prospective Studies / Quality of life / Risk analysis / Risk Factors / Sex hormones / Tamoxifen / Tamoxifen - adverse effects / Tamoxifen - therapeutic use / Teenagers / Womens health / Young Adult / Youth